M&A / Deals Otsuka grows in neuroplastogens with $1.225bn Transcend buy PharmaphorumOtsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials.M&A / DealsNeuroscienceRead full story pharminent March 29, 2026 (Last updated: March 30, 2026) Pharmaphorum Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based neuroplastogen drug candidate for PTSD, heading for phase 3 trials. M&A / DealsNeuroscienceRead full story Post navigation Previous: Lilly puts up to $2.75bn into Insilico allianceNext: Trustworthy AI in clinical oversight Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
